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The role of growth hormone (GH) during childhood and adulthood is well established.
Once final stature is reached, GH continues to act during the transition, the period
between adolescence and adulthood in which most somatic and psychological
development is obtained. The achievement of peak bone mass represents the most
relevant aspect of GH action during the transition period; however, equally clear is its
influence on body composition and metabolic profile and, probably, in the achievement of
a complete gonadal and sexual maturation. Despite this, there are still some aspects that
often make clinical practice difficult and uncertain, in particular in evaluating a possible
persistence of GH deficiency once final stature has been reached. It is also essential to
identify which subjects should undergo re-testing and, possibly, replacement therapy, and
the definition of unambiguous criteria for therapeutic success. Moreover, even during the
transition phase, the relationship between GH substitution therapy and cancer survival is
of considerable interest. In view of the above, the aim of this paper is to clarify these
relevant issues through a detailed analysis of the literature, with particular attention to the
clinical, diagnostic and therapeutic aspects.
Keywords: transition period, bone, body composition, metabolism, gonad function, growth hormone deficiency,
cancer survivorsINTRODUCTION
The importance and effectiveness of somatotropic hormone replacement therapy (rh-GH) in
children with low stature and/or linear growth decline associated with growth hormone deficiency
(GHD) is well established. In childhood, there is a diagnostic procedural standard and therapeutic
success can be easily evaluated based on the increase in the linear growth rate and the repositioning
in the family height target. Nevertheless, there are not the same certainties during the transition
period, both in diagnostic and therapeutic terms, even though it has been widely debated in the last
2 decades (1).n.org February 2021 | Volume 12 | Article 6342881
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height and ends with the achievement of peak bone mass. The
mean age of the transition onset differs according to sex and the
achievement of Prader’s pubertal stage 5 or final adult height.
According to Prader, in pubertal stage 5, the mean age is 14.7 ±
2.2 years in boys and 14.0 ± 2.4 years in girls; when considering
the final height, the mean age is 16.8 ± 2.2 years in boys and 15.2
± 2.0 years in girls, and in both cases with a growth velocity <1.5–
2 cm/year (2). The end of the transition period usually
corresponds with peak bone mass, which occurs at an average
age of 23.1 years in males and 19.9 years in females (3). Other
Authors define the end of the transition by referring to the sleep
chronotype, A percentage of between 25 and 100% of subjects,
which occurs at a mean age of 20.9 years for males or 19.5 years
for females (4).
The aim of this review is to address the main questions and
doubts related to transition, focusing on the diagnostic, clinical
and therapeutic tools.GHD DIAGNOSIS IN TRANSITION: THE
IMPORTANCE OF RE-TESTING
A percentage of between 25% and 100% of subjects with previous
childhood-onset GHD (CO-GHD) display a normalization of
GH secretion when undergoing re-testing (5).
It is usually recommended 1–3 months between the end of the
childhood rh-GH and the time of re-testing (6). This period
should not exceed 6 months (5, 7). Of note, not all subjects need
to be re-tested: patients with more than two pituitary hormone
deficits; isolated GHD associated with an identified mutation and
or a specific pituitary/hypothalamic structural defect, except for
an ectopic posterior pituitary; the presence of a transcription-
factor mutation (6, 8). The positive predictive value for GHD in
adulthood is 96% in the presence of three or more pituitary
hormone deficiencies and even 99% in the case of four hormone
deficits (9). Re-testing should be carried out in the following
cases: idiopathic isolated GHD with or without a small pituitary/
ectopic posterior pituitary; GHD associated with only one other
pituitary hormone deficiency; patients previously treated with
radiation therapy.
Table 1 provides a systematic list of the different available
provocative tests, with their respective cut-off values. The gold
standard is the Insulin Tolerance Test (ITT) (10–12). In the case
of contraindications, such as seizures or confirmed
cerebrovascular and cardiovascular risk factors, an alternative
is the Glucagon test (10, 14). Another tool used for the diagnosis
of GHD is the Arginine test, but it has been shown not to be very
effective (11). Finally, the GHRH+Arginine test is not
recommended in case of idiopathic GHD, because it may result
in a false-positive response (8, 10). In addition, a 2005 study
showed that this test should not be used for the diagnosis of
GHD in those adults treated with cranial irradiation (CRT) for
childhood acute lymphoblastic leukemia, as it could result in a
false-positive response (15). For this test, the Italian Medical
Agency set the cut-off value to 19 mg/L (16). A recent studyFrontiers in Endocrinology | www.frontiersin.org 2investigated the diagnostic accuracy of the GHRH+Arginine test
concluding that it should provide specific cut-off points
depending on the pathological condition, such as congenital
GHD, isolated GHD, multiple pituitary hormone defects and
cancer survivors (17).
The possibility of anticipating the time of re-testing, to avoid a
hypothetical over-treatment, has been recently investigated by
Penta and colleagues (18). The Authors claimed that it would be
useful to re-test patients with idiopathic and isolated GHD before
reaching final stature or Tanner stage 5, in order to avoid
over-treatment.
A special mention should be made of IGF-1: a normal or high
IGF1 value alone cannot rule out the diagnosis of GHD (19), as
well as a low value alone is not sufficient to make the diagnosis
(17, 20). Moreover, to date the chemiluminescence immunoassay
should be the preferred method as it is considered the most
appropriate and accurate (21).THE ROLE OF GH DURING TRANSITION:
EFFECTS ON BONE, BODY
COMPOSITION, METABOLISM, AND
GONADAL FUNCTION
There are numerous studies on the effect and importance of GH
during the transition phase. Most of them focus on the influence
on bone, metabolism and body composition. In this section, we
will also mention the impact of GH on fertility.
Bone
GH and its mediator IGF-1 have a cumulative effect of raising
bone turnover and mass, leading to an increase in endochondral
ossification and linear growth.
Although most studies in the literature agree on the role of
GH in improving bone quality, there is no unequivocal opinionTABLE 1 | List of the different available GH provocative tests, whit their
respective cut-off values.
Test BMI Cut-off References
GHRH +
Arginine test
BMI <25 kg/m2 <11 mg/L (8, 10)
BMI 25–30 kg/m2 <8 mg/L (8, 10)












<3 mg/L (10, 14)
BMI 25–30 kg/m2 (low
pretest probability)
<1 mg/L (10, 14)
BMI >30 kg/m2 <1 mg/L (10, 14)
Arginine test <0.4 mg/L (11)February 2021 | Volume 12 | Article 634288
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(RCTs), Carroll and Drake respectively showed an increase in
total body BMC (TB-BMC) of about 6% and lumbar spine BMC
(LS-BMC) of about 5% in treated subjects compared to untreated
(22, 23). In a 2-year RCT, an increase of 5% in the total body-
bone mineral density (TB-BMD) was found in subjects treated
with rh-GH, compared to 1.3% of untreated patients (24). In
another 2-year RCT, subjects were randomized either to an adult
dose of rh-GH or to a paediatric dose or to a placebo, with an
increase of TB-BMD, respectively of 3.3%, 5%, and 1.3% (25). By
contrast, another multicentre RCT study, in which 18 GHD
subjects were randomized to rh-GH and 15 to placebo, no
substantial increase in BMD between the two groups was
demonstrated (26). The same findings were obtained by Boot
and Hyldstrup (27, 28).
A 2014 cross-sectional study compared 18 subjects with
previous CO-GHD diagnosis, who were further subdivided
into two sub-groups of nine patients, each based on the
persistence or not of GHD after re-testing, with 18 healthy
subjects. They showed a reduction in TB-BMD and LS-BMD
both in GHD and in non-GHD subjects compared to controls,
demonstrating that the previous administration of rh-GH was
not sufficient to determine a normal BMD (29).
Of note, CO-GHD patients tend to have smaller bones than
control subjects; this may lead to underestimation of Areal BMD
assessed by dual energy X-ray absorptiometry (DXA) scan (30,
31) and contribute to discrepancies in the interpretation of
results among different investigations. Therefore, it should be
considered that those patients with CO-GHD, not treated with
rh-GH during childhood, have a significant reduction of the
Areal BMD, but a normal Volumetric BMD.
Some studies also assessed the impact of GH on the micro-
architectural characteristics of bone. A significant increase in
both BMD and in cortical thickness in subjects undergoing rh-
GH has been found by Hyldstrup et al (28)., whereas another
study found a significant reduction in cortical bone area and
thickness in untreated CO-GHD adults compared with AO-
GHD (32). Of note, there are no studies that unequivocally
demonstrate an increased risk of fractures in GHD subjects
during the transition (33, 34).
It should be noted that changes related to eating habits,
physical activity and socioeconomic status of patients might
occur during rh-GH and they can influence the outcome of
bone, metabolic, cardiac and body composition parameters. This
makes it more difficult to understand the weight of rh-GH alone
in all these changes. Moreover, other pituitary deficiencies and
their treatments could play a role in bone metabolism, as the
prevalence of fractures is markedly increased in patients with
multiple pituitary deficiencies (35).Body Composition
Some studies highlighted that a long period off rh-GH induces a
consistent increase in the percentage of fat mass (FM) and trunk
fat, with a decrease in lean mass (LM) (36–38). During theFrontiers in Endocrinology | www.frontiersin.org 3transition phase, several papers argued that in patients with a
GHD persistence and that do not resume rh-GH, there was a
reduction in LM and an increase in FM compared to control
subjects or those who resumed rh-GH. The LM decreased by
about 8%, compared to an average increase of about 15% in FM
(22, 39, 40). The resumption of rh-GH, showed a clear
improvement, with an increase in LM of about 14% and a
decrease in FM of about 7% after 2 years of therapy (24, 41).
In contrast, Mauras et al. found no improvement in body
composition after 2 years of treatment (26).
Another paper investigated early body composition changes
after the rh-GH break in a population with persistent GHD,
finding a significant increase in FM especially in those with
multiple pituitary deficits, and a significant reduction in cross-
sectional muscle area Z-score (42).
GH exerts considerable effects on skeletal muscle, inducing a
global effect of muscle growth through the stimulation of free-
fatty acids and amino-acid uptake, and the increase of protein
synthesis. Rh-GH should not be used during the transition with
the only aim of muscle growth, even though several studies have
shown clear lower muscle strength in confirmed GHD subjects
compared to sufficient or healthy controls (43). A recent study
assessed how 12 weeks of resistance exercise alone could improve
muscle strength during the transition (44). Interesting is the
interconnection between GH, leptin and ghrelin. Leptin, that
reduces the sense of appetite, is primarily secreted by white
adipose tissue, and its concentration correlates positively with
total FM. Ghrelin has an opposite effect and is mainly secreted by
P/D1 cells lining the fundus of the stomach and epsilon cells in
the pancreas. Ghrelin represents a powerful stimulator to GH
secretion, as it is a natural ligand for the GH-secretagogue
receptor (45). In a study by Roemmler and colleagues, it was
shown that rh-GH was able to reduce the total FM and
consequently the leptin levels, albeit there was a no significant
increase of ghrelin (46). This connection between GH, ghrelin
and leptin paves the way for the possible role of GH in appetite
regulation (47).Metabolic Aspects and
Cardiovascular Risk
Many studies report a worsening of the lipid pattern after
discontinuation of the rh-GH (41, 42, 48), although others do
not show any substantial difference between patients who resume
therapy and subjects who do not (22, 24, 26).
As a general statement we can say that the later treatment
begins in childhood and the longer the period off rh-GH lasts
during the transition, the worse the lipid profile becomes, with
higher total cholesterol and triglyceride levels (49), suggesting
that discontinuation of rh-GH during the transition is associated
with a pro-atherogenic lipid profile.
Some studies also demonstrated the influence of GH on post-
prandial lipid values. Lanes and co-Authors, in 2004, showed an
increase in post-prandial triglyceride values (4 h after a high-fat
meal) and peripheral inflammatory and fibrinolytic markers inFebruary 2021 | Volume 12 | Article 634288
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levels of basal triglycerides and overlapping values of post-
prandial triglycerides compared to an age-matched control
group have been found in a population of GHD subjects. This
metabolic situation remained unchanged after 4 months of rh-
GH (51).
Regarding the effects on glucose metabolism, there are no
unequivocal results. While some papers reported an improvement
in insulin sensitivity following therapy discontinuation after
reaching final stature (52), other studies came to opposite
conclusions. One study, in particular, reported a significant
increase in insulin resistance following a period of 6 months off
rh-GH, which tended to disappear 6months after the resumption of
therapy (53). Some papers highlighted a possible gender-specific
difference in carbohydrate metabolism and body composition.
Specifically, in a 2004 metanalysis, it is reported that males are
more sensitive to the effect of rh-GH on insulin sensitivity (54).
Regarding body composition, women seem to be less sensitive than
men, and require higher rh-GH doses to achieve the same
benefits (55).
There is currently insufficient data to determine whether rh-
GH may induce an increased risk of type 2 diabetes mellitus in
the future.
The effects of rh-GH on the heart were evaluated in an
echocardiographic study, which compared 21 previously
treated patients with 21 age- and sex-matched healthy controls.
The Authors found that in the 21 studied patients both the heart
height and size were lower than in the controls, despite long-
term rh-GH during childhood. Then, eight of the 21 patients
were subjected again to rh-GH for 15 months during the
transition period and they showed a significant increase in left
ventricular mass and an improvement in endothelial function
within the first 6 months of restarting rh-GH (56). Finally, a 2003
study reported an increase of intima-media thickness (IMT) in
subjects with previous CO-GHD, compared to both adult-onset
GHD patients and to controls (57); however, this finding was not
confirmed in two further studies (53, 58).. An interesting study,
carried out in 20 GH-naive Brazilian adults, due to a
homozygous mutation in GHRH receptor gene, demonstrated
a significant improvement in their lipid metabolic profile after 6
months of rh-GH, while a progressive increase in the number of
atherosclerotic carotid plaques was still noted. Moreover, a
relevant increase in both cardiac structural parameters (left
ventricular mass index, posterior wall, and septum thickness)
and carotid IMT was found after 6–12 months of rh-GH
suspension (59).
In relation to vascular reactivity, a study conducted in 10
GHD-treated adolescents, 12 GHD untreated adolescents and 14
controls, noted a lower flow-mediated endothelium-dependent
increase in the diameter of the brachial artery during hyperemia
in untreated subjects. In addition, the hyperemia-induced blood
flow increase was higher in treated patients than in controls and
in untreated GHD adolescents. The presence of such vascular
abnormalities, together with the increased epicardial adipose
tissue thickness, lead to an increased cardiovascular risk inFrontiers in Endocrinology | www.frontiersin.org 4non-treated subjects, even though it is reversible after rh-GH
(60). Abnormal vascular reactivity in young GHD adults was also
confirmed in a previous study, which demonstrated a reduction
of the brachial artery vasodilation induced by specific
vasodilators (acetylcholine and sodium nitroprusside) in seven
childhood-onset GHD patients. However, these vascular
abnormalities were not confirmed in subjects with CO-GHD
who had received adequate rh-GH, confirming that GHD was a
trigger (61).
Finally, rh-GH can also influence blood pressure. Most of the
studies argue that rh-GH induces a reduction in diastolic blood
pressure and no change in systolic blood pressure, through an
increase in nitric oxide formation, stimulation of the renin-
aldosterone system and decrease in intima-media thickness
(62). To date, there is only a study in which rh-GH was clearly
associated with hypertension (63).
GH and Gonadal Function
The effect of rh-GH on gonadal function has been widely
investigated, since it influences the hypothalamic-pituitary-
gonadal axis, facilitating the release of GnRH and consequently
of gonadotropins (64).
In 1994 our group described the effect of the rh-GH on the
improvement of spermatogenesis in 10 infertile patients presenting
with idiopathic severe oligozoospermia, normogonadotropinemia,
or moderate hypergonadotropinemia, with low IGF-1 values or
values within the lower limit of the normal range. Short-term rh-
GH led to an improvement in both sperm concentration and
motility in 50% of subjects (65). In a subsequent paper, we ruled
out the possibility of prolonged rh-GH use negatively affecting
testicular development or function (66).
In women, IGF-1 plays a role in the proliferation and
differentiation of granulosa cells and stimulates steroidogenesis
in large follicles and theca cells. Furthermore, a recent study
showed that GH, along with IGF-1, interacts with local ovarian
factors, such as VEGF-A and FGF-2, thus being a necessary actor
in the ovarian angiogenesis (67).IMPACT ON QUALITY OF LIFE
The impact of rh-GH on the quality of life (QoL) of GHD
patients during the transition period seems less clear than
in adulthood.
However, Abs and co-authors showed a positive relationship
between stature gain after rh-GH in childhood and the improved
QoL during the transition, while a negative relationship between
the duration of rh-GH discontinuation and QoL was reported
(34). Another paper evaluated through a survey the impact of rh-
GH on QoL at baseline and after 1 and 2 years of rh-GH, finding
that body shape and sexual arousal were significantly lower after
rh-GH suspension, thus negatively affecting the QoL (68). In
contrast to Mauras’ paper (26), several studies agreed that rh-GH
is effective in improving QoL, with a significant positive change
in health-related aspects (68, 69).February 2021 | Volume 12 | Article 634288
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another couple of studies, which showed a worsening of the
QoL after 1 year of rh-GH suspension, counterbalanced
following 6 months of rh-GH resumption (70, 71).
WHAT IS THE RIGHT THERAPEUTIC
DOSAGE DURING THE TRANSITION?
During the transition, the tendency is to start with an
intermediate dose between 0.22 and 0.30 mg/kg/week as in
childhood and 0.01–0.1 mg/kg/week as in adulthood (72).
In case the therapy was suspended after reaching final height,
it should be resumed at a dosage of 0.21 mg/kg/week, and then
titrate based on age, IGF-1 values, clinical response and the
possible appearance of adverse effects (73). However, based on
our clinical practice, we recommend starting with the lowest
therapeutic dose and then adjust dosage according to IGF-1
levels, clinical response and absence (even minimal) of adverse
effects. Table 2 summarises the possible main side effects
associated with rh-GH.
In women receiving oral oestrogen replacement therapy,
higher doses of rh-GH are typically required, as oral
oestrogens seem to attenuate the metabolic actions of GH on
its liver receptor, lowering IGF-1 secretion. It would therefore be
preferable to use transdermal oestrogens, in order to avoid/
attenuate the effect on the liver (74).
Regarding the production of thyroid hormones, rh-GH can
cause a slight reduction in FT4 and TSH levels, and an increase in
FT3 and could therefore unmask central hypothyroidism (75).
Therefore, before starting rh-GH and during treatment, thyroid
function should be monitored closely, particularly in the first
6 months.
At the adrenal level, GH can reduce the activity of the enzyme
11bHSD1, resulting in reduced conversion of cortisone to
cortisol. Thus, an assessment of the HPA axis function
(through the evaluation of basal AM and PM cortisol levels
and, when needed, after stimulation, e.g., ACTH test or ITT)
should be made before and after starting rh-GH, as GHD could
mask the presence of a hidden central hypoadrenalism (76).
Rh-GH, even during the transition, must be carefully
monitored to avoid the onset of possible adverse events. Every
6 months, it is advisable to carry out a haematochemical
screening, with the evaluation of IGF-1, serum glucose, HbA1c
and lipid profile, and a clinical evaluation based essentially on the
measurement of weight and waist circumference and bloodFrontiers in Endocrinology | www.frontiersin.org 5pressure. Every year a possible improvement in bone mineral
density through a DXA scan, and of the intima media thickness
by ultrasound examination should be evaluated, as well as any
positive changes in QoL (12).
GH TREATMENT IN CANCER SURVIVORS
DURING TRANSITION
GHD is the most frequent endocrine disorder in childhood
cancer survivors, especially in those with a history of pathology
(and treatments) of the hypothalamic-pituitary region (20). In
this respect, there is no unequivocal data on the risk of
recurrence, as several studies indicate a very low or no-risk
(77–80), whereas others provide no certain conclusions (81). The
same risk of recurrence in GH-treated cancer survivors
compared to non-treated subjects was found in two different
studies (82, 83).
Others found no increased risk of cancer recurrence in a rh-
GH treated paediatric population (84) and in patients with
previous brain cancer (85, 86). As to the risk of developing a
secondary neoplasm, a recent meta-analysis indicated that rh-
GH seems not increase this risk (87). However, opposite results
were found in other relevant studies, such as CCSS, GeNeSIS,
and HypoCCS, in which the percentage of second neoplasms was
3.8% in GeNeSIS and 6% in HypoCCS (77, 88).
The Endocrine Society suggests starting rh-GH 1 year after
stopping cancer therapy, when there is no more evidence of cancer
disease. In the case of chronic or not totally eradicable oncological
diseases, the choice whether to start rh-GH or not should be
tailored according to the characteristics of the tumor and the
patient, after a proper discussion with the oncologist (20).
A very controversial topic is the choice of the therapeutic rh-
GH dose. However, it should be appropriate to use the minimum
effective dose so as to decrease symptomatology. The most widely
used and free of side effects therapy is the daily administration of
0.21 mg/kg/week, adjusted so as to reach normal IGF-1
levels (89).
To summarise, papers published so far show that
somatotropin is indicated in those patients who have GHD
and it appears safe in terms of tumor recurrence. Of course,
caution is extremely important in the follow-up of GHD patients
during the transition period, but it would be inappropriate to
deprive them of therapy that is central to treating this deficiency.
CONCLUSIONS
Transition is a period in life in which the maturation of the
organism is completed. During the transition, GH plays a relevant
role on bone maturation, metabolism and body composition.
GHD increases cardiovascular risk and impacts fertility
negatively. For these reasons, GH is considered extremely
important for a good quality of life. There are still uncertainties
about when and how to re-test to confirm or not a persistent GHD
in patients previously treated with somatotropin, and there is still
no total agreement regarding the therapeutic dosage. The link
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increased recurrence risk in these patients during the transition.
Further studies with a longer duration of rh-GH are needed,
in order to assess with more accuracy, the effects of rh-GH
during the transition, and eliminate those uncertainties that are
still present on this fascinating but often too feared hormone.Frontiers in Endocrinology | www.frontiersin.org 6AUTHOR CONTRIBUTIONS
All the authors have made a substantial, direct and intellectual
contribution to the work. MS revised it critically. All authors
approved the work for publication. All authors contributed to the
article and approved the submitted version.REFERENCES
1. Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM,
et al. American association of clinical endocrinologists and American college
of endocrinology guidelines for management of growth hormone deficiency
in adults and patients transitioning from pediatric to adult care. Endocr Pract
(2019) 25(11):1191–232. doi: 10.4158/GL-2019-0405
2. Prader A, Largo RH, Molinari L, Issler C. Physical growth of Swiss children
from birth to 20 years of age. First Zurich longitudinal study of growth and
development. Helv Paediatr Acta (1989) 52:1–125.
3. Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, Keizer-
Schrama SM. Peak bone mineral density, lean body mass and fractures. Bone
(2010) 46(2):336–41. doi: 10.1016/j.bone.2009.10.003
4. Roenneberg T, Merrow M. The circadian clock and human health. Curr Biol
(2016) 26(10):R432–43. doi: 10.1016/j.cub.2016.04.011
5. Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S, et al.
Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of
GH status and evaluation of the predictive criteria for permanent GHD in
young adults. J Clin Endocrinol Metab (1999) 84(4):1324–8. doi: 10.1016/
j.cub.2016.04.011
6. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M. European
Society of Paediatric Endocrinology. Consensus statement on the
management of the GH-treated adolescent in the transition to adult care.
Eur J Endocrinol (2005) 152(2):165–70. doi: 10.1530/eje.1.01829
7. Radovick S, DiVall S. Approach to the growth hormone-deficient child during
transition to adulthood. J Clin Endocrinol Metab (2007) 92(4):1195–200.
doi: 10.1210/jc.2007-0167
8. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML.
Endocrine Society. Evaluation and treatment of adult growth hormone
deficiency: an Endocrine Society clinical practice guideline. J Clin
Endocrinol Metab (2011) 96:1587–609. doi: 10.1210/jc.2011-0179
9. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ.
HyposCCS Advisory Board; U.S. HypoCCS Study Group. Which patients do
not require a GH stimulation test for the diagnosis of adult GH deficiency? J
Clin Endocrinol Metab (2002) 87(2):477–85. doi: 10.1210/jcem.87.2.8216
10. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association
of Clinical Endocrinologists. American Association of Clinical
Endocrinologists medical guidelines for clinical practice for growth
hormone use in growth hormone deficient adults and transition patients—
2009 update. Endocr Pract (2009) 15(Suppl 2):1–29. doi: 10.4158/EP.15.6.580
11. Aimaretti G, Attanasio R, Cannavò S, Nicoletti MC, Castello R, Di Somma C,
et al. Growth hormone treatment of adolescents with growth hormone
deficiency (GHD) during the transition period: results of a survey among
adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED,
AME, SIE, SIMA. J Endocrinol Invest (2015) 38(3):377–82. doi: 10.1007/
s40618-014-0201-7
12. Secco A, di Iorgi N, Napoli F, Calandra E, Calcagno A, Ghezzi M, et al.
Reassessment of the growth hormone status in young adults with childhood-
onset growth hormone deficiency: reappraisal of insulin tolerance testing. J
Clin Endocrinol Metab (2009) 94(11):4195–204. doi: 10.1210/jc.2009-0602
13. Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, et al.
Overweight/Obese adults with pituitary disorders require lower peak growth
hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis
of growth hormone deficiency. J Clin Endocrinol Metab (2014) 99(12):4712–9.
doi: 10.1210/jc.2014-2830
14. Loche S, Di Iorgi N, Patti G, Noli S, Giaccardi M, Olivieri I, et al. Growth
Hormone Deficiency in the Transition Age. Endocr Dev (2018) 33:46–56.
doi: 10.1159/00048752515. Björk J, Link K, Erfurth EM. The utility of the growth hormone (GH) releasing
hormone-arginine test for diagnosing GH deficiency in adults with childhood
acute lymphoblastic leukemia treated with cranial irradiation. J Clin
Endocrinol Metab (2005) 90(11):6048–54. doi: 10.1210/jc.2005-0304
16. Corneli G, Di Somma C, Prodam F, Bellone J, Bellone S, Gasco V, et al. Cut-off
limits of the GH response to GHRH plus arginine test and IGF-I levels for the
diagnosis of GH deficiency in late adolescents and young adults. Eur J
Endocrinol (2007) 157(6):701–8. doi: 10.1530/EJE-07-0384
17. Patti G, Noli S, Capalbo D, Allegri AME, Napoli F, Cappa M, et al. Accuracy
and Limitations of the Growth Hormone (GH) Releasing Hormone-Arginine
Retesting in Young Adults With Childhood-Onset GH Deficiency. Front
Endocrinol (Lausanne) (2019) 10:525:525. doi: 10.3389/fendo.2019.00525
18. Penta L, Cofini M, Lucchetti L, Zenzeri L, Leonardi A, Lanciotti L, et al.
Growth Hormone (GH) Therapy During the Transition Period: Should We
Think About Early Retesting in Patients with Idiopathic and Isolated GH
Deficiency? Int J Environ Res Public Health (2019) 16(3):307. doi: 10.3390/
ijerph16030307
19. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, Neelis KJ, Biermasz
NR, Romijn JA, et al. Pituitary dysfunction in adult patients after cranial
radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab
(2011) 96(8):2330–40. doi: 10.1210/jc.2011-0306
20. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, et al.
Hypothalamic-Pituitary and Growth Disorders in Survivors of Childhood
Cancer: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol
Metab (2018) 103(8):2761–84. doi: 10.1210/jc.2018-01175
21. Ho KKGH Deficiency Consensus Workshop Participants. Consensus
guidelines for the diagnosis and treatment of adults with GH deficiency II:
a statement of the GH Research Society in association with the European
Society for Pediatric Endocrinology, Lawson Wilkins Society, European
Society of Endocrinology, Japan Endocrine Society, and Endocrine Society
of Australia. Eur J Endocrinol (2007) 157(6):695–700. doi: 10.1530/EJE-07-
0631
22. Carroll PV, Drake WM, Maher KT, Metcalfe K, Shaw NJ, Dunger DB, et al.
Comparison of continuation or cessation of growth hormone (GH) therapy
on body composition and metabolic status in adolescents with severe GH
deficiency at completion of linear growth. J Clin Endocrinol Metab (2004) 89
(8):3890–5. doi: 10.1210/jc.2003-031588
23. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hübner C, Shaw
NJ, et al. The effect of cessation of growth hormone (GH) therapy on bone
mineral accretion in GH-deficient adolescents at the completion of linear
growth. J Clin Endocrinol Metab (2003) 88(4):1658–63. doi: 10.1210/jc.2002-
021541
24. Underwood LE, Attie KM, Baptista J. Genentech Collaborative Study Group.
Growth hormone (GH) dose-response in young adults with childhood-onset
GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled
study. J Clin Endocrinol Metab (2003) 88(11):5273–80. doi: 10.1210/jc.2003-
030204
25. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalová J, et al.
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